girentuximab
heidelberg pharmaceuticals,esteve,prometheus
['solid tumor', 'rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)', 'zircon', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sarcoma', 'girentuximab', 'imab ']
exciting data from the ph 3 zircon trial for me, secondary endpoint of sensitivity/specificity in ct1a masses most clinically meaningful: 3 cm srm deciding between robo pnx vs biopsy vs cryo vs as #gu23 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday